Ascofuranone inhibits epidermal growth factor -induced cell migration by blocking epithelial-mesenchymal transition in lung cancer cells

被引:2
作者
Kim, Hyo-Weon [1 ,2 ]
Jeong, Yun-Jeong [1 ,2 ]
Hwang, Soon-Kyung [1 ,2 ]
Park, Yoon-Yub [1 ,2 ]
Choi, Yung Hyun [3 ]
Kim, Cheorl-Ho [4 ]
Magae, Junji [5 ]
Chang, Young-Chae [1 ,2 ]
机构
[1] Catholic Univ Daegu, Sch Med, Res Inst Biomed Engn, Daegu 42472, South Korea
[2] Catholic Univ Daegu, Sch Med, Dept Med, Daegu 42472, South Korea
[3] Dong Eui Univ, Dept Biochem, Coll Korean Med, Busan 47227, South Korea
[4] Sungkyunkwan Univ, Dept Biol Sci, Suwon 440746, Kyunggi Do, South Korea
[5] Magae Biosci Inst, 49-4 Fujimidai, Tsukuba, Ibaraki 3001263, Japan
基金
新加坡国家研究基金会;
关键词
DOWN-REGULATION; C-MYC; INVASION; PATHWAY; PROLIFERATION; EXPRESSION; RECEPTORS; VIMENTIN; MOTILITY;
D O I
10.1016/j.ejphar.2020.173199
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ascofuranone, an isoprenoid antibiotic initially purified from a culture broth of Ascochyta viciae, has multiple anticancer effects. However, the impacts of ascofuranone on the epithelial–mesenchymal transition (EMT) and epidermal growth factor (EGF)-induced effects on human lung cancer cell lines have not been previously reported. Here, we show that ascofuranone exerts its anticancer effects by inhibiting the EGF-induced EMT and cell migration in human lung cancer cell lines. Ascofuranone significantly inhibited EGF-induced migration and invasion by lung cancer cells, and suppressed EGF-induced morphologic changes by regulating the expression of EMT-associated proteins. In addition, ascofuranone upregulated E-cadherin, and downregulated fibronectin, vimentin, Slug, Snail, and Twist. Inhibition of ERK/AKT/mTOR promoted EGF-induced E-cadherin downregulation and inhibited EGF-induced vimentin upregulation in response to ascofuranone, implying that inhibition of the EGF-induced EMT by ascofuranone was mediated by the ERK and AKT/mTOR pathways. Inhibition of c-Myc suppressed EGF-induced vimentin upregulation, suggesting the involvement of c-Myc. Collectively, these findings suggest that ascofuranone inhibits tumor growth by blocking the EGF-induced EMT through a regulatory mechanism involving ERK, AKT/mTOR, and c-Myc in lung cancer cells. © 2020 Elsevier B.V.
引用
收藏
页数:9
相关论文
共 35 条
  • [1] Liquid Biopsy Enables Quantification of the Abundance and Interindividual Variability of Hepatic Enzymes and Transporters
    Achour, Brahim
    Al-Majdoub, Zubida M.
    Grybos-Gajniak, Agnieszka
    Lea, Kristi
    Kilford, Peter
    Zhang, Mian
    Knight, David
    Barber, Jill
    Schageman, Jeoffrey
    Rostami-Hodjegan, Amin
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (01) : 222 - 232
  • [2] Ascofuranone suppresses PMA-mediated matrix metalloproteinase-9 gene activation through the Ras/Raf/MEK/ERK- and Ap1-dependent mechanisms
    Cho, Hyun-Ji
    Kang, Jeong Han
    Kwak, Jong-Young
    Lee, Tae-Sung
    Lee, In-Seon
    Park, Nam Gyu
    Nakajima, Hiroo
    Magae, Junji
    Chang, Young-Chae
    [J]. CARCINOGENESIS, 2007, 28 (05) : 1104 - 1110
  • [3] Lipid mediator Leukotriene D4-induces airway epithelial cells proliferation through EGFR/ERK1/2 pathway
    Dholia, Neeraj
    Yadav, Umesh C. S.
    [J]. PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2018, 136 : 55 - 63
  • [4] EGF-Mediated Overexpression of Myc Attenuates miR-26b by Recruiting HDAC3 to Induce Epithelial-Mesenchymal Transition of Lens Epithelial Cells
    Dong, Ning
    Xu, Bing
    Xu, Jingmei
    [J]. BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [5] The Epithelial-Mesenchymal Transition (EMT) Regulatory Factor SLUG (SNAI2) Is a Downstream Target of SPARC and AKT in Promoting Melanoma Cell Invasion
    Fenouille, Nina
    Tichet, Melanie
    Dufies, Maeva
    Pottier, Anais
    Mogha, Ariane
    Soo, Julia K.
    Rocchi, Stephane
    Mallavialle, Aude
    Galibert, Marie-Dominique
    Khammari, Amir
    Lacour, Jean-Philippe
    Ballotti, Robert
    Deckert, Marcel
    Tartare-Deckert, Sophie
    [J]. PLOS ONE, 2012, 7 (07):
  • [6] Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer
    Fumarola, Claudia
    Bonelli, Mara A.
    Petronini, Pier Giorgio
    Alfieri, Roberta R.
    [J]. BIOCHEMICAL PHARMACOLOGY, 2014, 90 (03) : 197 - 207
  • [7] Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting
    Gialeli, Chrisostomi
    Theocharis, Achilleas D.
    Karamanos, Nikos K.
    [J]. FEBS JOURNAL, 2011, 278 (01) : 16 - 27
  • [8] The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    Jakobsen, Kristine Raaby
    Demuth, Christina
    Sorensen, Boe Sandahl
    Nielsen, Anders Lade
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (02) : 172 - 182
  • [9] p53-Independent Induction of G1 Arrest and p21WAF1/CIP1 Expression by Ascofuranone, an Isoprenoid Antibiotic, through Downregulation of c-Myc
    Jeong, Ji-Hak
    Kang, Shin-Sung
    Park, Kwan-Kyu
    Chang, Hyeun-Wook
    Magae, Junji
    Chang, Young-Chae
    [J]. MOLECULAR CANCER THERAPEUTICS, 2010, 9 (07) : 2102 - 2113
  • [10] Ascofuranone suppresses EGF-induced HIF-1α protein synthesis by inhibition of the Akt/mTOR/p70S6K pathway in MDA-MB-231 breast cancer cells
    Jeong, Yun-Jeong
    Cho, Hyun-Ji
    Magae, Junji
    Lee, In-Kyu
    Park, Keun-Gyu
    Chang, Young-Chae
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2013, 273 (03) : 542 - 550